Quantcast

Latest Élan Stories

2008-07-22 03:00:18

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving TYSABRI treatment. Specifically, as of the end of June 2008: -- In the US,...

2008-07-18 03:00:50

DUBLIN, Ireland, July 18, 2008 (PRIME NEWSWIRE) -- Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms...

2008-06-18 12:01:00

Elan and Wyeth have announced positive preliminary findings from a Phase II study of bapineuzumab in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease. The study did not attain statistical significance on the primary efficacy endpoints in the overall study population. However, post-hoc analyses did show statistically significant and clinically meaningful benefits in important subgroups....

2008-06-18 12:00:11

The much anticipated results of a clinical trial of one of the more promising Alzheimer's drugs, released June 17, were mixed at best. But in the Alzheimer's world that qualifies as a success -- and on Wall Street, it was a winner as well. Wyeth Pharmaceuticals (WYE) and Elan Corp. (ELN) announced that the Phase II trial of their jointly developed drug, bapineuzumab, did not attain statistically significant results in the overall group of 240 patients. But in a subset of patients that...

2006-04-07 03:51:55

By Michael Smith DUBLIN (Reuters) - Elan Corp. Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri showed significant positive results in patients, sending its shares higher. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last...

2006-04-07 01:44:27

DUBLIN (Reuters) - Elan Corporation Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri on sufferers showed significant positive effects on their quality of life. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last month after...

2006-03-08 15:07:29

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec's multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect. If the Food and Drug Administration followed the recommendation, it would signal a reversal of fortune for Biogen and partner Elan Corp. of Ireland, and a victory for MS patients who have pleaded for...

2006-03-08 13:36:22

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri can return to the market as long as there are safeguards to closely monitor patients for a life-threatening side effect, a U.S. advisory panel unanimously said on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended Tysabri sales in February 2005 after three patients developed a rare brain and spinal cord infection and two of them died. Members of the U.S. Food and...

2006-03-08 11:45:00

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan Corp.'s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday. Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection. Two of them died.

2006-03-08 10:59:41

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related